Form 4 for ZVRA ZEVRA THERAPEUTICS, INC.
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-07 · accession 0001681098-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-10 | 2026-02-09 | ZVRA | McFarlane Neil F. | Pres, CEO, Dir | S - Sale+OE | $8.56 | -14.6K | 387.2K | -4% | -$125.2K |
| D | 2026-02-10 | 2026-02-07 | ZVRA | McFarlane Neil F. | Pres, CEO, Dir | M - OptEx | — | +37.5K | 401.9K | +10% | — |
| D | 2026-02-10 | 2026-02-07 | ZVRA | McFarlane Neil F. | Pres, CEO, Dir | M - OptEx | $0.00 | -37.5K | 75.0K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | S | D | 14,625 | $8.56 | 387,225 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $8.39 to $8.67. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2026-02-07 | M | A | 37,500 | — | 401,850 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 3 | Derivative | Restricted Stock Unit | 2026-02-07 | M | D | 37,500 | $0.00 | 75,000 | D | — · — to — | 37,500 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. |